RemeGen Co., Ltd. (09995)

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

RemeGen Co., Ltd. (09995)

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various can

CS Hotline: +852 3018 4526

Trading days: 24 hours | Non-trading days: 9:00-18:00

Headquarters

Sheung Wan

Address: Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong

North District

Address: 1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong

Email: cs@usmart.hk

WhatsApp: +852 5989 2641

uSMART Branches(Causeway Bay coming soon)

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907) holding Type 1 Licence for Dealing in Securities, Type 4 Licence for Advising on Securities, Type 6 Licence for Advising on Corporate Finance, and Type 9 Licence for Asset Management.

Market News

RemeGen Co., Ltd. (09995)

Services

About Us

Agreement Statement